Organ-on-a-Chip Resources

Advanced pathophysiology mimicking lung models for accelerated drug discovery

Phan et al., 2023

This new publication highlights the importance of detailed critical evaluation of the human-relevance and reliability of in vitro models. We are thrilled to see the successes the Chrzanowski lab have had by using the PhysioMimix system to generate these novel MPS models which mimic healthy and normal human lungs.

Characterization of the effect of primary human hepatocytes (PHH) lots of functions in CN Bio Innovations Liver-Chip using acetaminophen

In this study, the FDA explore donor-to-donor variability in toxicology endpoints. Plus, how selecting the best combination of cells to accurately represent a given population is key to reducing the variability.

Immune-mediated DILI – Predicting the unpredictable!

Dr Anthony Berger discusses the limitations of the existing workflow and how organ-on-a-chip can help to predict the unpredictable, immune-mediated DILI.

Introducing PhysioMimix HT

Our latest in the PhysioMimix organ-on-a-chip (OOC) range. The groundbreaking PhysioMimix HT (higher throughput)! Designed to overcome the adoption challenges of OOC technology.

PhysioMimix Organ-on-a-Chip Brochure

Explore our full range of PhysioMimix organ-on-a-chip systems with our new brochure. Featuring our next-generation PhysioMimix HT (higher throughput).

PhysioMimix Single-organ HT system

Discover the data behind our new groundbreaking PhysioMimix HT system and Liver48 plate. Plus why it is a game-changer in the industry.

Organ-on-a-chip provides preclinical safety toxicologists with the tools to combat drug attrition

Learn how organ-on-a-chip technology is aiding toxicologists in de-risking drug-induced liver injury by providing human-specific safety data.

This article is taken from Select Science, February 2023

Organ-on-a-chip models in drug development

Learn how organ-on-a-chip (OOC) technologies succeed where organoids and spheroids fail, bridging the remaining gap between existing 2D/3D models and the human.

This article is taken from Drug Discovery World, January 2023

About CN Bio…

Ever wondered what differentiates CN Bio, the people behind our brand, why we come to work every morning or our vision for the future? Here’s a snapshot of us in 3 minutes. We hope you enjoy it!

The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, what can be embraced in its place?

What is the FDA Modernization Act 2.0, and what does it mean?

Normalization of organ-on-a-Chip samples for mass spectrometry based proteomics and metabolomics via Dansylation-based assay

Gallagher et al., 2022

This study shows the importance of normalization for paired MS-based multi-omics-OOC studies to accurately investigate highly toxic hazards and their effects on the human liver. Using VX, a highly toxic chemical compound, the study identifies VX-specific toxic effects on 3D liver tissues as well as specific hepatic cellular biomarkers and pathways affected by the toxic agent.

Modelling the intestine-liver axis: The role of FXR agonists in a multi-organ microphysiological system model of non-alcoholic fatty liver disease

Here, we demonstrate the potential of a liver and a gut/liver microphysiological systems (MPS) to recapitulate NAFLD and NASH phenotypes in vitro and explore the molecular mechanisms underlying the development of NAFLD/NASH as well as assess the efficacy of novel therapeutic strategies.